secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001828185-24-000022
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio reports Phase 1b/2 VTP-200 trial: safety met but pooled efficacy not statistically significant
--------------------------------------------------------------------------------

- APOLLO trial met primary safety endpoint; VTP-200 well-tolerated with no treatment-related Grade 3+ AEs or SAEs.
- Highest hrHPV clearance 60% (group 2, highest ChAdOx dose) vs 33% placebo; cervical lesion clearance 67% (groups 2&5) vs 39% placebo.
- Pooled data across all active dose groups showed no statistically significant improvement in hrHPV or cervical lesion clearance vs placebo.
- Company evaluating future development options for VTP-200; further analyses ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000022/0001828185-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000022/brns-20240418.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer